Clinical Trial

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2019-03-29; most recent amendment 2025-12-02.
Status change: Recruiting → Active, Not Recruiting 2025-12-02
Status change: Active, Not Recruiting → Recruiting 2023-05-12
Status change: Recruiting → Active, Not Recruiting 2021-12-09
Status change: Not Yet Recruiting → Recruiting 2019-07-29
Trial Details
NCT Number NCT03897881
Lead Sponsor ModernaTX, Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions Melanoma
Enrollment 267 participants
Start Date 2019-07-18
Primary Completion 2032-11-30 (estimated)
Study Completion 2032-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-03